P/E ratio for Arrowhead Pharmaceuticals (ARWR)

P/E ratio history for Arrowhead Pharmaceuticals from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Alnylam Pharmaceuticals ALNY	-59.7	421.95%	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA
Ligand Pharmaceuticals LGND	73.0	-738.21%	🇺🇸 USA
Inovio Pharmaceuticals INO	-2.83	-75.26%	🇺🇸 USA
Johnson & Johnson JNJ	10.3	-189.65%	🇺🇸 USA
Moderna MRNA	-4.31	-62.33%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.